Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTP4000 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TTP4000 1.0 mg/kg | EXPERIMENTAL | Administered subcutaneously |
| TTP4000 3.0 mg/kg | EXPERIMENTAL | Administered subcutaneously |
| Placebo | PLACEBO_COMPARATOR | Administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| TTP4000 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Males or females ≥ 50 years of age. * Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive. * Weight ≥ 50 kg. * Alzheimer's disease according to the DSM-IV-TR criteria and a score between 20 and 26 on the Mini Mental State Exam. * Subject must have a medical history for at least...
Top 20 of 24 competitors
TTP4000 is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being developed by vTv Therapeutics Inc. for use in patients with this neurological condition.
TTP4000 is being developed by vTv Therapeutics Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VTVT. The company is conducting clinical research on this investigational small molecule for Alzheimer's Disease, with the drug currently in Phase 1 development.
TTP4000 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for Alzheimer's Disease, and its Phase 1 trial has been completed, though it remains in early-stage clinical development.
TTP4000 has one completed clinical trial registered under NCT01548430, titled "A Safety Study of TTP4000 in Subjects With Alzheimer's Disease." This Phase 1 study enrolled 8 participants in the United States, was randomized, double-blind, and placebo-controlled, and included patients aged 50 years and older.
No, TTP4000 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Alzheimer's Disease. The drug has completed a Phase 1 safety study, but it has not yet received regulatory approval and remains in the early stages of clinical testing.